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least 50 counts for the NanoString abundance analyses.
MiR raw data was normalized using the geometric mean
of top 100 miRs (probes with highest 100 counts) as
recommended by the manufacturer. Fold change was
calculated with partitioning by the low- vs high-risk
groups computing two-tailed t-test on the log trans-
formed normalized data that assumes unequal variance.
We used p-value cut-off of <0.1 to identify relevant
miRs. Heat-map analysis used z-score transformation on
samples computing Spearman correlation of the median
between samples.
Among 654 tested miRs, 7 were under-expressed and 12
were over-expressed among the high- vs low-risk group
(Table provided with ﬁgure). Agglomerative cluster “heat-
map” analysis of 16 samples representative of both groups is
shown in Figure.
We identiﬁed a group of MiRs as biomarkers for
pre-transplant relevant comorbidities and increased
post-transplant mortality. Validation of ﬁndings and
determination of gene associations in a larger dataset is
under way.451
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Introduction: Philadelphia chromosome (PH) positive (+)
acute lymphoblastic leukemia (ALL) is incurable without
undergoing allogeneic hematopoietic stem cell transplant
(HCT). Ideally patients should be in complete remission (CR)
prior to HCT without minimal residual disease (MRD). Center
for International Blood and Marrow Research data shows
that ALL patients 20 years of age receiving matched sibling
HCT between 2001-2011, the 3-year survival probabilities
were 53%  1%, 32%  2%, and 23%  2% for patients with
early, intermediate, and advanced disease, respectively.
Corresponding probabilities among the 3,929 recipients of
unrelated donor HCTwere 50% 1%, 34% 2%, and 18% 2%.
Recognizing that patients with PH + ALL have aggressivedisease we questioned if there were factors that would pre-
dict relapse or prevent relapse post HCT in this cohort.
Methods: The HCT database at Mayo Clinic Arizonawas used
to identify patients with Ph + ALL undergoing transplant
from January 1994 through December 2013. 20 PH+ patients
were identiﬁed. Demographic and HCT data were taken from
this database. Data on tyrosine kinase inhibitor (TKI) use and
chimerism were obtained retrospectively from the patient
record.
Results: 6 (30%) patients relapsed and 5 died from their
disease. 1 patient died from transplant related mortality. 5
year survival rate was 59.5%. Of the 6 patients who relapsed
none were MRD positive pre HCT, 3 had 100% donor
chimerism at day 100 and 3 started a TKI post HCT. The 3who
started a TKI did so at day 80, 169 and 172. Conditioning
regimen for these 6 patients consisted of: Fludarabine/
Melphalan/Busulfan (2), Fludarabine/Melphalan (1), Etopo-
side/Cyclophosphamide/Total Body Irradiation (1) and
Cyclophosphamide/Total Body Irradiation (1 ). At HCT 2 pa-
tients were in CR1, 1 in CR2 and 1 in CR3. 1 patient came to
HCT in relapse but did not relapse after. 15 of the 20 patients
were placed on a TKI post HCT. No statistically signiﬁcant
factor was detected to impact relapse or overall survival.
Discussion: PH + ALL is a disease with a poor prognosis. This
study shows a 60% overall survival at 5 years post HCT which
is better than has been reported. We had hypothesized that if
patients were not started on a TKI, had PH + MRD pre or post
HCT, did not reach 100% chimerism at day 100 or did not
receive radiation as part of the conditioning regimen it
would impact relapse. Though this is a small descriptive
study it is notable that there were no trends observed. In the
era where we have many TKIs to choose from perhaps our
outcomes in PH positive ALL are improving. Future research
should focus on conditioning regimen for ALL (full versus
reduced intensity, radiation versus no radiation), optimal
time to start a TKI post HCT and does MRD by PCR pre and
post HCTmatter. Certainly in this study of 20 patients none of
these factors was statistically signiﬁcant. Future study of a
larger population would be prudent.
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Background: The use of monoclonal antibodies in combi-
nation with chemotherapy for the treatment of lymphoma
may improve efﬁcacy by utilizing distinct mechanisms of
tumor kill while minimizing overlapping toxicity. Bend-
amustine, a bifunctional alkylating agent, has been usedwith
Rituximab in indolent non-Hodgkin lymphomas, chronic
lymphocytic leukemia, and more recently for the treatment
relapsed and refractory diffuse large B-cell lymphomas
(DLBCL).
Brentuximab, a monoclonal antibody targeting CD30, is
approved for refractory and relapsed anaplastic large cell lym-
phoma, Hodgkin lymphoma relapsed after autologous stem cell
transplant and may have efﬁcacy in the treatment of DLBCL
which have been shown to express CD30 in 14-25% of cases.
We report the Mount Sinai Hospital experience using
bendamustine and brentuximab (BB) in the treatment of
relapsed-refractory lymphomas and its utility as a bridge to
transplant.
Methods: Retrospective analysis of the tolerability and out-
comes for patients receiving BB between 2013 and 2014 as
part of quality assurance review.
Results: Seven patients (1 female) were identiﬁed with a
median age of 39 (range 34-70). Diagnoses included Hodgkin
lymphoma (4), primary mediastinal B-cell lymphoma (1),
DLCBL (1), and peripheral T-cell enteropathy associated type
II lymphoma (1). Median time between initial diagnosis
and BB was 19 months (range 12-175 months). Patients
received a mean of 4.1 prior lines of therapy (range 2-9)
including allogeneic transplantation (1) and autologous
transplantation (4).
All patients received 90 mg/m2 of bendamustine and 1.8
mg/kg of brentuximab approximately every 3 weeks for a
mean of 2.71 cycles. Two patients developed sepsis and
fungal pneumonia, respectively. Of 6 patients evaluable for
response, 4 had partial response, 1 hadmixed response and 1
had PR after 2 cycles, then received a stem cell boost/DLI but
ultimately died from progression of disease (POD). 2 other
patients received allogeneic stem transplants and 3 patients
are awaiting transplantation.
Conclusion: BB in our heterogeneous and heavily pre-
treated population has been well tolerated, has provided
disease control, and has enabled patients to be bridged to
transplant, both allogeneic and autologous.Table.
Patient Diagnosis Age/Sex # of BB Cycles
1 Hodgkin Lymphoma 42/F 3
2 Primary Mediastinal
B cell lymphoma
34/M 3
3 Hodgkin Lymphoma 41/M 4
4 DLBCL 36/M 4
5 Hodgkin Lymphoma 36/M 2
6 Hodgkin Lymphoma 39/M 2
7 Peripheral T cell lymphoma,
enteropathy associated type 2
70/M 1453
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Introduction: HLA-haploidentical bone marrow trans-
plantation using posttransplant high-dose cyclophospha-
mide (Cy) has been increasingly performed, but relapse
remains a major problem. To test whether the addition of
busulfan to the conditioning regimen and the use of pe-
ripheral blood stem cells (PBSCs) instead of bone marrow
could reduce relapse, we conducted a multicenter phase II
study to evaluate the safety and efﬁcacy of posttransplant
Cy-based HLA-haploidentical peripheral blood stem cell
transplantation (PBSCT) after busulfan-containing reduced-
intensity conditioning.
Patients and Methods: This study started in May 2013 (Trial
identiﬁer: UMIN000010316). Patients aged from 15 to 65
with hematological malignancies who were planned for
HLA-haploidentical PBSCT were enrolled. The conditioning
regimen consisted of ﬂudarabine (30 mg/m2/day on days -6
to -2), Cy (14.5 mg/kg/day on days -6 and -5), busulfan (3.2Response Outcome
PR after 2 cycles Died POD
PR after 2 cycles Alive
s/p cord blood transplant
PR after 2 cycles Alive
Awaiting allogeneic transplant
PR after cycle 2, stable
disease after cycle 4
Alive
Awaiting allogeneic transplant
Mixed response after 2 cycles Alive
s/p cord blood transplant
Awaiting imaging s/p 2 cycles Alive
Awaiting autologous transplant
N/A Alive
Awaiting allogeneic transplant
